Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex Effects

Hypertension

Volumn 65, Issue 6, 2015, Pages 1209-1216

  Grassi, Guido ^a,b   Seravalle, Gino ^c   Brambilla, Gianmaria ^a   Trabattoni, Daniela ^d   Cuspidi, Cesare ^a,c   Corso, Rocco ^a,e   Pieruzzi, Federico ^e   Genovesi, Simonetta ^e   Stella, Andrea ^e   Facchetti, Rita ^a   Spaziani, Domenico ^f   Bartorelli, Antonio ^d   Mancia, Giuseppe ^a,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d CENTRO CARDIOLOGICO MONZINO   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f Ospedale di Magenta   (Italy)

Author keywords

hypertension resistant to conventional therapy; pressoreceptors; sympathetic nervous system

Indexed keywords

ALDOSTERONE ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; KIDNEY DENERVATION; MALE; MIDDLE AGED; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESISTANT HYPERTENSION; SAMPLE SIZE; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE; BLOOD PRESSURE MEASUREMENT; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY; PHYSIOLOGY; PROCEDURES; REFERENCE VALUE; RISK ASSESSMENT; SYMPATHECTOMY; TIME; TREATMENT OUTCOME; VASCULAR RESISTANCE;

AGED; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CASE-CONTROL STUDIES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SYMPATHECTOMY; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84937605550     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04823     Document Type: Article

References (33)

1. Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, Spaziani D, Cuspidi C, Mancia G. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177:1020-1025. doi: 10.1016/j.ijcard.2014.09.138.
2. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934. doi: 10.1056/NEJMc0904179.
3. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-1490. doi: 10.1161/HYPERTENSIONAHA.112.201186.
4. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-464. doi: 10.1161/HYPERTENSIONAHA.111.00194.
5. Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, Lambert GW, Esler MD, Schlaich MP. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014;64:118-124. doi: 10.1161/HYPERTENSIONAHA.113.03098.
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419. doi: 10.1161/HYPERTENSIONAHA.108.189141.
7. Böhm M, Mahfoud F, Ukena C, et al. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. EuroIntervention. 2013;9:484-492. doi: 10.4244/EIJV9I4A78.
8. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804-1814. doi: 10.1161/CIRCRESAHA.114.302524.
9. Sealey JE, Laragh, JH. How to do a plasma renin assay. Cardiovasc Med. 1977;2:1079-1092.
10. Ojima M, Aida M, Kambegawa A. Simultaneous determination of plasma 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, and aldosterone in man. Tohoku J Exp Med. 1978;124:367-379.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
12. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
14. Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB. Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr. 1996;9:119-128.
15. Kienbaum P, Karlssonn T, Sverrisdottir YB, Elam M, Wallin BG. Two sites for modulation of human sympathetic activity by arterial baroreceptors? J Physiol. 2001;531(Pt 3):861-869.
16. Kjeldsen SE, Os I, Mahfoud F. Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects. EuroIntervention. 2013;9(suppl R):R7-R9. doi: 10.4244/EIJV9SRA1.
17. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, Mancia G. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998;97:2037-2042.
18. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381. doi: 10.1056/NEJM199602083340607.
19. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262(6 Pt 1):E763-E778.
20. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, MD: American Physiological Society; 1983:755-793.
21. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, Bauer A. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013;62:2124-2130. doi: 10.1016/j.jacc.2013.07.046.
22. Wallin BG, Esler M, Dorward P, Eisenhofer G, Ferrier C, Westerman R, Jennings G. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol. 1992;453:45-58.
23. Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol. 1996;491(Pt 3):881-887.
24. Lambert GW, Thompson JM, Turner AG, Cox HS, Wilkinson D, Vaz M, Kalff V, Kelly MJ, Jennings GL, Esler MD. Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects. J Auton Nerv Syst. 1997;64:57-64.
25. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal dnervation. Am J Physiol. 2010;298:R245-R253.
26. Kubota J, Nishimura H, Ueyama M, Kawamura K. Effects of renal denervation on pressure-natriuresis in spontaneously hypertensive rats. Jpn Circ J. 1993;57:1097-1105.
27. Wang Y, Denton KM, Golledge J. Control of salt and volume retention cannot be ruled out as a mechanism underlying the blood pressure-lowering effect of renal denervation. Hypertens Res. 2013;36:1006-1007. doi: 10.1038/hr.2013.82.
28. Kowalski R, Kreft E, Kasztan M, Jankowski M, Szczepanska-Konkel M. Chronic renal denervation increases renal tubular response to P2X receptor agonists in rats: implication for renal sympathetic nerve ablation. Nephrol Dial Transplant. 2012;27:3443-3448. doi: 10.1093/ndt/gfs087.
29. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045. doi: 10.1016/j.jacc.2013.08.1616.
30. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, Laufs U, Neuberger HR, Böhm M. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-2851. doi: 10.1016/j. ijcard.2012.07.027.
31. Ewen S, Mahfoud F, Linz D, Pöss J, Cremers B, Kindermann I, Laufs U, Ukena C, Böhm M. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. Hypertension. 2014;63:839-845. doi: 10.1161/HYPERTENSIONAHA.113.01985.
32. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752-1759. doi: 10.1093/eurheartj/ehu209.
33. Bhatt DL, Kandzari DE, ONeill WW, DAgostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.